<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1102">
  <stage>Registered</stage>
  <submitdate>17/03/2006</submitdate>
  <approvaldate>17/03/2006</approvaldate>
  <nctid>NCT00304759</nctid>
  <trial_identification>
    <studytitle>PROFIT - Prostate Fractionated Irradiation Trial</studytitle>
    <scientifictitle>A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CIHR grant MCT-78776</secondaryid>
    <secondaryid>OCOG-2005-PROFIT</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - 7800 cGy/39 fractions in 8 weeks
Treatment: surgery - 6000 cGy/20 fractions in 4 weeks

Experimental: 1 - 6000 cGy / 20 fractions in 4 weeks

Active Comparator: 2 - 7800 cGy / 39 fractions in 8 weeks


Treatment: surgery: 7800 cGy/39 fractions in 8 weeks
see above

Treatment: surgery: 6000 cGy/20 fractions in 4 weeks
see above

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Biochemical (PSA) Failure</outcome>
      <timepoint>five years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical-Clinical Failure</outcome>
      <timepoint>five years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prostate Cancer Specific Mortality</outcome>
      <timepoint>five years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>five years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>five years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologic diagnosis of carcinoma of the prostate within 6 months of entry without
             evidence of metastatic disease to the lymph nodes, bone or lung;

          2. Intermediate risk prostate cancer (that is, T1-2a, Gleason score &lt;6, PSA 10.1-20.0
             ng/ml; T2b-c Gleason &lt;6, PSA = 20.0 ng/ml; T1-2, Gleason 7, PSA = 20.0 ng/ml).</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Histologic diagnosis of carcinoma of the prostate more than six months prior to study
             entry;

          2. Previous therapy for carcinoma of the prostate other than biopsy or transurethral
             resection;

          3. Patients previously on more than 12 weeks of hormone therapy for treatment of their
             prostate cancer;

          4. Any other active malignancy (untreated, progressive or recurrent), except for
             non-melanoma skin cancer. Any inactive malignancy diagnosed within 5 years of entry,
             except for non-melanoma skin cancer;

          5. Treatment plan cannot meet dose constraints for the hypofractionation arm of the
             trial;

          6. Previous pelvic radiotherapy;

          7. Inflammatory bowel disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1204</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Liverpool Hospital &amp; Campbelltown Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Newcastle Hospital - Newcastle</hospital>
    <hospital>Northern Sydney Cancer Centre, Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Westmead Cancer Care Centre - Wentworthville</hospital>
    <hospital>Wollongong Hospital / Illawarra Cancer Care Centre - Wollongong</hospital>
    <hospital>Toowoomba Cancer Research Centre - Toowoomba</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Ballarat Austin Radiation Oncology Centre (BAROC) - Ballarat</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2310 - Newcastle</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4350 - Toowoomba</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>8006 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Ontario Clinical Oncology Group (OCOG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Institutes of Health Research (CIHR)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Trans-Tasman Radiation Oncology Group (TROG)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is designed to determine whether an 8-week course of escalated dose conformal
      radiation can be compressed safely, and with similar efficacy into a 4-week course.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00304759</trialwebsite>
    <publication>Martin J, Frantzis J, Chung P, Langah I, Crain M, Cornes D, Plank A, Finch T, Jones M, Khoo E, Catton C. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (A TROG-OCOG Intergroup Project). Radiother Oncol. 2013 Jun;107(3):333-8. doi: 10.1016/j.radonc.2013.05.015. Epub 2013 Jun 8.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Charles Catton, MD</name>
      <address>Princess Margaret Hospital, Canada</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>